Biological Characterization Study of an Autograft Nanofat (Nanocarabio)

Rhizarthrosis (trapeziometacarpal osteoarthritis) is the most common primary osteoarthritis of the hand, and a source of major functional impact, as it affects the thumb. Non-surgical therapeutic means are currently limited to wearing an immobilization splint, analgesics and oral non-steroidal anti-inflammatory drugs. These symptomatic treatments are of limited effectiveness and do not prevent from progression of the osteoarthritis disease. The most effective treatments currently recognized are surgical, but they also have their limits. Cell therapy is considered as a promising approach to treat tissue damage including osteoarthritis. Mesenchymal stromal cells are excellent candidates for achieving this type of result, because they can differentiate into the different tissues from the mesoderm (cartilage, bone, muscle, tendons, fat, dermis, conjunctive matrix, etc.). In addition, unlike cells from the embryonic cord, the risk of teratoma or tumor does not exist. Mesenchymal stem cells have regenerative and immunomodulatory properties but the methods of collection, preparation, combination with substances such as hyaluronic acid, or PRP, or platelet concentrates, will obviously influence the effectiveness of the results. . Nanofat autografts are obtained in a simple way, in a closed circuit, preserving the stromal mesenchymal cells in large numbers with a minimum impact on the cellular elements. The preparation remains simple and inexpensive, but it is nevertheless necessary to characterize these emulsified preparations biologically before using them as cell therapy. The main objective of this study is to characterize a nanofat autograft on a biological level.

Inclusion Criteria: 1. Volunteers, men or women, aged at least 20 to 75 years old. 2. BMI ≥ 20 Kg/m² (in order to have adipose tissue in quantity sufficient) 3. Volunteers who signed an informed consent 4. Hemoglobinemia \> 10g/dl 5. Negative Beta-HCG assay 6. Volunteers benefiting from or affiliated to a social security scheme Exclusion Criteria: 1. Thrombocytopenia \< 150 G/L 2. Thrombocytosis \> 450 G/L 3. Known thrombopathy 4. TP \< 70% 5. APT Patient/Control ratio \> 1.20 6. Anemia \< 10g/dl 7. Taking antiplatelet, aspirin, anti vitamin K dating less than 15 days before inclusion 8. Fever or recent infection (bacterial or viral) dating from less than a month 9. Autoimmune diseases confirmed by questioning, or clinical and/or biological elements (inflammatory assessment: VS, CRP, fibrinogen) and may interfere with the quality of autograft 10. Inflammatory arthritis 11. Microcrystalline Arthritis 12. Immunodeficiency 13. Current or chronic infectious diseases (viral or bacterial) attested by clinical elements and/or biological (inflammatory assessment: ESR, CRP, Fibrinogen) 14. Malignant tumor under treatment or history of malignant tumor 15. BMI \< 20 Kg/m² 16. Contraindication to local anesthesia or surgery 17. Pregnant or breastfeeding women 18. Adults protected by law (under guardianship and guardianship) 19. People participating simultaneously in another research involving the human person 20. Miners 21. Persons staying in a health or social establishment 22. People in an emergency situation 23. Persons deprived of liberty 24. Persons not covered by a social security scheme